CureVac (NASDAQ:CVAC) Azioni

CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

Quali sono le aziende pronte a rispondere all&#39;emergenza e come potrebbe impattare sul mercato azionario? Ecco i dettagli.

Allarme influenza aviaria: nuovo caso in USA. Ecco 4 azioni da tenere d&#39;occhio

CureVac NV

Wells Fargo analyst Gabe Hajde maintains Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Equal-Weight and lowers the price target from $53 to $43.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Smurfit WestRock, Lowers Price Target to $43

Wells Fargo analyst Gabe Hajde maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Overweight and lowers the price target from $236 to $209.

Wells Fargo Maintains Overweight on Packaging Corp of America, Lowers Price Target to $209

Wells Fargo analyst Gabe Hajde maintains International Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) with a Equal-Weight and lowers the price target from $52 to $45.

Wells Fargo Maintains Equal-Weight on International Paper, Lowers Price Target to $45

Wells Fargo analyst Alec Brondolo maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Equal-Weight and lowers the price target from $22 to $19.

Wells Fargo Maintains Equal-Weight on Unity Software, Lowers Price Target to $19

UBS analyst Thomas Wadewitz maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $557 to $422.

SAIA

UBS Maintains Buy on Saia, Lowers Price Target to $422

UBS analyst Thomas Wadewitz maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Neutral and lowers the price target from $196 to $158.

ODFL

UBS Maintains Neutral on Old Dominion Freight Line, Lowers Price Target to $158

UBS analyst Thomas Wadewitz maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and lowers the price target from $170 to $108.

UBS Maintains Buy on XPO, Lowers Price Target to $108

UBS analyst Trung Huynh maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and lowers the price target from $28 to $24.

UBS Maintains Neutral on Pfizer, Lowers Price Target to $24

Seaport Global analyst Tom Curran maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Sell and lowers the price target from $1 to $0.75.

PLUG

Seaport Global Maintains Sell on Plug Power, Lowers Price Target to $0.75

Citigroup analyst Paul Diamond maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Sell and lowers the price target from $22 to $19.

Citigroup Maintains Sell on Magnolia Oil & Gas, Lowers Price Target to $19

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and lowers the price target from $320 to $280.

CVNA

Citigroup Maintains Buy on Carvana, Lowers Price Target to $280

Citigroup analyst Christopher Allen maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and lowers the price target from $84 to $75.

NDAQ

Citigroup Maintains Neutral on Nasdaq, Lowers Price Target to $75

BLNK

Blink Charging Receives Letter From Nasdaq Regarding Late Filing Of Form 10-K

Citigroup analyst Scott Gruber maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Buy and lowers the price target from $33 to $32.

Citigroup Maintains Buy on Helmerich & Payne, Lowers Price Target to $32

Unifirst Announces New $100M Share Repurchase Authorization

Citigroup analyst Scott Gruber maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and lowers the price target from $54 to $53.

Citigroup Maintains Buy on Baker Hughes, Lowers Price Target to $53

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $423 to $375.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $375

Citigroup analyst Patrick Cunningham maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $135 to $113.

Citigroup Maintains Buy on PPG Indus, Lowers Price Target to $113

Citigroup analyst Patrick Cunningham maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy and lowers the price target from $99 to $84.

Citigroup Maintains Buy on Intl Flavors & Fragrances, Lowers Price Target to $84

NSYS

Nortech Systems Reveals New Patent For Non-Magnetic Expanded Beam Fiber Optic Cable Technology.

Press Releases

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Earnings

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Comments

CureVac

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO